Table 2 Comparisons of clinical outcomes
Outcomes | Usual care group (n = 42) | VAC-optimized group (n = 40) | P value |
|---|---|---|---|
Primary outcome | |||
28-day mortality, n (%) | 21 (50) | 13 (33) | 0.061 |
Secondary outcomes | |||
Lactate clearance rate (%), median (IQR) | 18.3 (−5.7, 32.1) | 27.7 (11.9, 45.7) | 0.038 |
Length of ICU stay (days), median (IQR) | 9 (5, 13) | 13 (5, 24) | 0.106 |
Duration of IMV (days), median (IQR) | 9 (4, 15) | 9 (5, 23) | 0.594 |
Other outcomes | |||
Dose of norepinephrine (μg/kg/min), median (IQR) | 0.222 (0.148, 0.445) | 0.196 (0.094, 0.301) | 0.094 |
Inotropic drugs, n (%) | 10 (24) | 19 (48) | 0.025 |
Dobutamine | 10 (24) | 17 (43) | 0.072 |
Infused dose (μg/kg/min), mean ± SD | 6.54 ± 2.63 | 5.49 ± 2.86 | 0.354 |
Levosimendan | 0 (0) | 1 (3) | 0.488 |
Milrinone | 0 (0) | 2 (5) | 0.235 |
Cumulative fluid volume during the study period (mL/kg), mean ± SD | 22.1 ± 9.0 | 18.9 ± 13.9 | 0.216 |
Urine output (mL/kg/h), median (IQR) | 1.15 (0.75, 1.79) | 1.17 (0.66, 1.71) | 0.659 |